2 research outputs found
Asymmetric Synthesis of a Glucagon Receptor Antagonist via Friedel–Crafts Alkylation of Indole with Chiral α‑Phenyl Benzyl Cation
Development of a practical asymmetric synthesis of a
glucagon receptor
antagonist drug candidate for the treatment of type 2 diabetes is
described. The antagonist consists of a 1,1,2,2-tetrasubstituted ethane
core substituted with a propyl and three aryl groups including a fluoro-indole.
The key steps to construct the ethane core and the two stereogenic
centers involved a ketone arylation, an asymmetric hydrogenation via
dynamic kinetic resolution, and an <i>anti</i>-selective
Friedel–Crafts alkylation of a fluoro-indole with a chiral
α-phenyl benzyl cation. We also developed two new efficient
syntheses of the fluoro-indole, including an unusual Larock-type indole
synthesis and a Sugasawa-heteroannulation route. The described convergent
synthesis was used to prepare drug substance in 52% overall yield
and 99% ee on multikilogram scales
Asymmetric Synthesis of a Glucagon Receptor Antagonist via Friedel–Crafts Alkylation of Indole with Chiral α‑Phenyl Benzyl Cation
Development of a practical asymmetric synthesis of a
glucagon receptor
antagonist drug candidate for the treatment of type 2 diabetes is
described. The antagonist consists of a 1,1,2,2-tetrasubstituted ethane
core substituted with a propyl and three aryl groups including a fluoro-indole.
The key steps to construct the ethane core and the two stereogenic
centers involved a ketone arylation, an asymmetric hydrogenation via
dynamic kinetic resolution, and an <i>anti</i>-selective
Friedel–Crafts alkylation of a fluoro-indole with a chiral
α-phenyl benzyl cation. We also developed two new efficient
syntheses of the fluoro-indole, including an unusual Larock-type indole
synthesis and a Sugasawa-heteroannulation route. The described convergent
synthesis was used to prepare drug substance in 52% overall yield
and 99% ee on multikilogram scales